



TITLE:

# CD16(+) natural killer cells play a limited role against primary dengue virus infection in tamarins.

AUTHOR(S):

Yoshida, Tomoyuki; Omatsu, Tsutomu; Saito, Akatsuki;  
Katakai, Yuko; Iwasaki, Yuki; Iijima, Sayuki; Kurosawa, Terue;  
... Yasutomi, Yasuhiro; Kurane, Ichiro; Akari, Hirofumi

---

CITATION:

Yoshida, Tomoyuki ...[et al]. CD16(+) natural killer cells play a limited role against primary dengue virus infection in tamarins.. Archives of virology 2012, 157(2): 363-368

ISSUE DATE:

2012-02

URL:

<http://hdl.handle.net/2433/153290>

RIGHT:

The final publication is available at [www.springerlink.com](http://www.springerlink.com); この論文は著者最終稿です。内容が印刷版と異なることがありますので、引用の際には出版社版をご確認ご利用ください。This is the Accepted Author Manuscript. Please cite only the published version.

**-BRIEF REPORT-**

**CD16 positive natural killer cells play a limited role against primary dengue virus infection in tamarins**

**Tomoyuki Yoshida · Tsutomu Omatsu · Akatsuki Saito · Yuko Katakai · Yuki Iwasaki · Sayuki Iijima · Terue Kurosawa · Masataka Hamano · Shinichiro Nakamura · Tomohiko Takasaki · Yasuhiro Yasutomi · Ichiro Kurane · Hirofumi Akari**

T. Yoshida (e-mail) · Y. Iwasaki · S. Iijima · T. Kurosawa · M Hamano · Y. Yasutomi · H. Akari (e-mail)

Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 1-1 Hachimandai, Tsukuba, Ibaraki 305-0843, Japan

E-mail: [akari@pri.kyoto-u.ac.jp](mailto:akari@pri.kyoto-u.ac.jp)

E-mail: [ytomoyuki@pri.kyoto-u.ac.jp](mailto:ytomoyuki@pri.kyoto-u.ac.jp)

T. Yoshida · A. Saito · H. Akari

Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto University, Inuyama, Aichi 484-8506, Japan

T. Omatsu · T. Takasaki · I. Kurane

Department of Virology I, National Institute of Infectious diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

A. Saito

International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

Y. Katakai

Corporation for Production and Research of Laboratory Primates, 1-1 Hachimandai, Tsukuba, Ibaraki 305-0843, Japan

S. Nakamura

Research Center for Animal Life Science, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan

36

37 Address corresponding: H. Akari, Primate Research Institute, Kyoto University,  
38 Inuyama, Aichi 484-8506, Japan. E-mail: [akari@pri.kyoto-u.ac.jp](mailto:akari@pri.kyoto-u.ac.jp)

39 Address co-corresponding: T. Yoshida, Primate Research Institute, Kyoto University,  
40 Inuyama, Aichi 484-8506, Japan. E-mail: [ytomoyuki@pri.kyoto-u.ac.jp](mailto:ytomoyuki@pri.kyoto-u.ac.jp)

41 TEL: +81-568-63-0456 FAX: +81-568-62-9559

42

43 T. Yoshida and T. Omatsu contributed equally to this study.

44

45 **Key words:** Dengue virus, tamarin, NK cells, CD16

46

46    **Abstract**

47    CD16 is a major molecule expressed on NK cells. To directly assess the role of natural  
48    killer (NK) cells in dengue virus (DENV) infection *in vivo*, CD16 antibody-treated  
49    tamarins were inoculated with DENV-2 strain. This resulted in the transient depletion of  
50    CD16<sup>+</sup> NK cells, whereas no significant effects on the overall levels or kinetics of  
51    plasma viral loads and anti-viral antibodies were observed in the treated monkeys as  
52    compared to those in the control monkeys. It remains elusive whether CD16<sup>+</sup> NK  
53    subpopulation could play an important role in the control of primary DENV infection.

54

DENV is one of the most serious mosquito-borne virus affecting humans with 2.5 billion people at risk in tropical and subtropical regions around the world each year [12]. A wide variety of clinical manifestations have been noted, which range from asymptomatic, mild febrile illness (dengue fever [DF]) to dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS), a life-threatening illness. It has been shown that humans with a secondary heterologous DENV infection are at a higher risk of contracting severe dengue disease [10, 26]. DHF/DSS occurs in infants during primary DENV infection predominantly in the second half of the first year of life when maternal antibodies have low residual neutralizing activity [11, 17].

NK cells are a component of the innate immune system that plays a central role in host defense against viral infection and tumor cells. It has been shown that infection by some viruses, such as herpes simplex virus-1, influenza virus or the ectromelia poxvirus, can be controlled by NK cells in mice [15]. Yet the most compelling evidence for a role of NK cells in early defense against viruses was obtained in a study showing increased susceptibility or resistance to murine cytomegalovirus (MCMV) after NK cell depletion or NK cell adoptive transfer, respectively [23]. Defects in NK cell activity, such as decreased production of interferon (IFN)- $\gamma$  or cytotoxicity, render mice more susceptible to MCMV infection [23]. NK cells can kill virus-infected cells by using cytotoxic granules or by recognizing and inducing lyses of antibody-coated target cells (antibody-dependent cell cytotoxicity) via Fc binding receptor such as CD16 [21].

Early activity of NK cells may be important for clearing primary DENV infection [24]. In a DENV mouse model, mice experimentally infected with DENV showed increased NK cell levels [24]. A significant increase in the frequency of NK cell circulation was also shown in patients who developed an acute dengue disease [2]. In addition, patients with a mild dengue disease have elevated NK cell rates when compared to those with severe dengue diseases [9, 27]. Moreover, Kurane *et al.* reported that human blood NK cells are cytotoxic against DENV-infected cells in target organs via direct cytotoxicity and antibody-dependent cell-mediated cytotoxicity [14]. It was also shown that the intracellular cytotoxic granule, TIA-1, was up-regulated early in NK cells in the acute phase of DENV infection and that NK-activating receptor NKp44 was involved in virus-mediated NK activation through direct interaction with DENV envelope protein [2, 13]. These results suggest that the early activation of NK cells contributes to the prevention of the severe dengue disease. However, based on quantitative and functional analyses in animal model *in vivo*, defining the contribution of NK cells to suppress DENV replication *in vivo* has been necessary.

We have recently reported that common marmosets (*Callithrix jacchus*) are highly permissive to DENV infection [22]. The New World monkeys, being nonhuman primates are considered to have a similar immune system to humans [28, 29]. The present study was initiated to investigate the role of NK cells in controlling DENV during primary infection in our nonhuman primate model.

The animals were cared for in accordance with National Institute of Biomedical Innovation rules and guidelines for experimental animal welfare, and all protocols were approved by our Institutional Animal Study Committee. Eight tamarins (*Saguinus midas* and *Saguinus labiatus*) were used in this study. As marmosets and tamarins are closely related monkey species and are classified into Callitrichinae, we expected that tamarins would also be permissive to DENV infection as well as marmosets. To check the permissiveness of tamarins to DENV, 2 tamarins were infected with DENV-2 (DHF0663 strain:  $6.7 \times 10^7$  PFU/ml) subcutaneously or intravenously (Fig. 1). Dengue viral RNA (vRNA), which was quantified using real-time PCR as previously described [22], was detected in plasma samples from the tamarins on day 1 post-infection. For each of the two tamarins (Tm03-011, Tm06-017), the plasma vRNA levels reached  $2.7 \times 10^6$  copies/ml and  $2.0 \times 10^7$  copies/ml on day 1 post-infection, respectively, and were detectable on days 3 and 5. These results indicate that tamarins are also permissive to DENV infection, which is consistent with the results obtained by using marmosets [22].

Next, we sought to assess the role of NK cells in DENV infection *in vivo*. In this regard, *in vivo* depletion of NK cells by the administration of NK-specific monoclonal antibody (mAb) was considered to be straightforward to directly address the question. We employed a new method by which an anti-CD16 mAb 3G8 [7] but not a control mAb MOPC-21 efficiently depleted a major NK population expressing CD16 in tamarins, as we recently reported [29]. The mouse anti-human CD16 mAb 3G8 was produced in serum-free medium and purified using protein A affinity chromatography. Endotoxin levels were confirmed to be lower than 1 EU/mg. Four red-handed tamarins and two white-lipped tamarins (*Saguinus labiatus*) were used in this experiment. Three tamarins were intravenously administered 3G8 at a dose of 50 mg/kg, while others were given a control mAb MOPC-21. One day later, both mAb-treated tamarins were subcutaneously inoculated with  $3 \times 10^5$  PFU/ml of DENV-2 DHF0663 strain on the basis of a previous report that a single mosquito might inject between  $10^4$  and  $10^5$  PFU of DENV into a human [20]. It was confirmed that at 1-3 days after the 3G8 mAb treatment, CD16<sup>+</sup> cells were almost completely depleted in the tamarins followed by recovery to the initial levels at around 2 weeks after administration, while the cells were

maintained at the initial levels in the monkeys with MOPC-21 (Fig. 2A). In addition, it is noteworthy that the ratios of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD20<sup>+</sup> B cells were not affected by the administration of the 3G8 mAb (Supplementary Figure 1). In the case of the MOPC-21 mAb administration, we confirmed no significant effect on CD16<sup>+</sup> cells (Supplementary Figure 2). The killing activities of the peripheral blood mononuclear cells (PBMCs) taken from the 3G8-treated monkeys were reduced at day 1 post antibody-treatment, followed by increase irrespective of depletion of CD16<sup>+</sup> NK cells at day 2 post antibody-treatment (1 day after DENV inoculation), suggesting that CD16<sup>-</sup> NK population may be activated by DENV infection (Fig. 2B). Plasma viral loads in both mAb-treated monkeys rose to 10<sup>5</sup> copies/ml by day 1 after infection and then reached a peak at 10<sup>6</sup> copies/ml on day 3 or day 7 followed by a rapid decline with values dipping below the detectable level by day 14 after infection (Fig. 2C). These results suggested that CD16<sup>+</sup> NK cells did not apparently contribute to DENV replication in the acute phase in our tamarin model.

It was previously reported that non-structural glycoprotein NS1 was essential for flavivirus viability and the NS1 protein circulated during the acute phase of disease in the plasma of patients infected with DENV [1]. Epidemiological studies have demonstrated that secreted NS1 levels are correlated with viremia levels and are higher in DHF than in dengue fever (DF) early in illness [16], thus it has been suggested that NS1 might be a useful marker as an indicator of the severity of dengue disease. We have used the value of the NS1 antigens as an alternative diagnostic marker to examine the effects of CD16 antibody treatment on DENV replication. The NS1 was measured by Platelia Dengue NS1 Ag assay (BioRad). Antigenemia was noted in these infected monkeys between 3-14 days post-infection. Serum IgM and IgG specific for DENV antigens were measured by ELISA. DENV specific IgM or IgG antibody was equally detected in both mAb-treated monkeys.

We recently demonstrated that marmosets were permissive to DENV infection [22]. In this study, we found that tamarins were also permissive to DENV infection (Fig.1). Moreover, we also investigated the role of NK cells against early DENV infection using *in vivo* depletion of CD16<sup>+</sup> NK cells in tamarins. As a result, the depletion of CD16<sup>+</sup> NK cells had almost no effect on DENV replication (Fig. 2), and thus the NK subpopulation was unlikely to contribute to controlling DENV replication. Interestingly, these results imply that CD16<sup>-</sup> NK subpopulation may have a critical role of controlling DENV infection *in vivo*.

Using our model, we investigated the roles of NK cells *in vivo* against DENV

infection, which remains to be elucidated in several aspects. We previously reported that almost complete *in vivo* depletion of CD16<sup>+</sup> NK subpopulation was not able to completely remove the NK-mediated cytotoxic activity in tamarins [29]. In this study, despite a transient but substantial reduction in CD16<sup>+</sup> NK cell number following 3G8 treatment in tamarins, DENV replication was comparable to that in monkeys with the control mAb. The NK-mediated cytotoxic activity was rather augmented in either study group, which indicates that CD16<sup>-</sup> NK cells was responsible for the cytotoxic activity and suggests that they might play a role in controlling DENV replication.

The next question is how CD16<sup>-</sup> NK cells may regulate DENV infection. One possibility regarding CD16<sup>-</sup> NK cells is that CD56<sup>+</sup> or CD57<sup>+</sup> NK cells are involved in controlling DENV infection. Human NK cells are classically divided into 2 functional subsets based on their cell surface density of CD56 and CD16, i.e. CD56<sup>bright</sup>CD16<sup>-</sup> immunoregulatory cells and CD56<sup>dim</sup>CD16<sup>+</sup> cytotoxic cells. Both subsets have been characterized extensively regarding their different functions, phenotypes, and tissue localization [8]. The NK cell number is maintained by a continuous differentiation process associated with the expression of CD57 that ends in NK cells with poor responsiveness to cytokine stimulation but high cytolytic capacity [3, 18]. The second possibility is that CD16<sup>-</sup> NK cells have non-cytolytic helper function. Generally, it is well known that NK cells possess both a cytolytic and a non-cytolytic helper function. It was suggested that cytokine production is carried out by CD56<sup>bright</sup>CD16<sup>-</sup> NK cells [4-6]. Interferon (IFN)- $\gamma$  secreted by NK cells has shown potent antiviral effects against DENV infection in early phases [25]. One aspect of the NK helper function arises from recent evidence indicating that NK cells can be induced to function as non-cytotoxic helper cells following stimulation with interleukin-18 [19]. This cytokine induces IFN- $\gamma$  secretion from NK cells and thus enables dendritic cells (DCs) to secrete IL-12, leading to Th1 polarization [19]. It is possible that CD16<sup>-</sup> NK cells, which have poor cytotoxic activity but the enhanced ability to secrete cytokines and then to lead Th1 response, are preserved during 3G8 administration. The persistence of this minor CD16<sup>-</sup> NK cell subpopulation could exert an antiviral effect through INF- $\gamma$ -mediated pathways despite the depletion of CD16<sup>+</sup> NK cells. The third possibility is that CD16<sup>+</sup> NK cells of tamarins play pivotal roles against bacterial infections and cancer progression but not DENV-infected cells. We will address these possibilities for the roles of the NK subpopulation in the future studies.

In conclusion, this study provides DENV replication model *in vivo* in tamarins and new information on the possible role of CD16<sup>+</sup> NK cells in DENV



194 replication *in vivo*. It remains elusive whether CD16<sup>+</sup> and CD16<sup>-</sup> NK subpopulation  
195 could play an important role in the control of primary DENV infection.  
196

196    **Acknowledgements**

197    We would like to give special thanks to members of the Corporation for Production and  
198    Research of Laboratory Primates for technical assistance. We also would like to give  
199    special thanks to Ms. Tomoko Ikoma and Ms. Mizuho Fujita for technical assistance.  
200    Moreover, we appreciate Dr. Keith A. Reimann (the NIH Nonhuman Primate Reagent  
201    Resource R24 RR016001, NIAID contract HHSN272200900037C) for providing CD16  
202    and CD8 antibodies. This work was supported by grants from the Ministry of Health,  
203    Labor and Welfare of Japan (to Hirofumi Akari and Ichiro Kurane). This research was  
204    also supported by the environment Research and Technology Development Fund  
205    (D-1007) from the Ministry of the Environment of Japan (to Tomoyuki Yoshida and  
206    Hirofumi Akari).  
207

## Figure legends

**Fig. 1** Levels of vRNA in DENV-infected tamarins. Tamarins were subcutaneously or intravenously infected with DENV at a dose of  $6.7 \times 10^7$  PFU/ml. The vRNAs were detected in plasma by real-time PCR. Tm03-011: Subcutaneously. Tm06-017: Intravenously.

**Fig. 2** Ratios of CD16<sup>+</sup> NK cells, killing activity of PBMCs, and vRNA in DENV-infected tamarins after treatment of 3G8 or MOPC-21 mAb. Tamarins were subcutaneously infected with DENV at a dose  $3 \times 10^5$  PFU/ml after treatment with 50mg/kg of 3G8 or MOPC-21 mAb. (A) Ratios of CD16<sup>+</sup> NK cells were determined in whole blood specimens. (B) The activities of NK cells were determined in PBMCs of tamarins by NK cytotoxic assay. (C) The vRNAs were detected in plasma by real-time PCR.

**Fig. 3** Levels of NS1 antigen and DENV-specific IgM and IgG in plasma samples from DENV-infected tamarins after treatment of 3G8 or MOPC-21 mAb. The levels of NS1 antigen and DENV-Specific IgM and IgG in plasma were measured by ELISA. ELISA index of NS1 antigen (A), the positive/negative (P/N) ratio of DENV-specific IgM (B), and P/N ratio of DENV-specific IgG (C) in plasma samples from DENV-infected tamarins after administration of the 3G8 or MOPC-21 mAb. The P/N ratio was calculated by the formula: the optical density of the test sample divided by that of a negative sample. P/N ratios of  $<2$  and  $\geq 2$  were considered to be negative and positive, respectively. Top: 3G8, Bottom: MOPC-21 mAb.

## 230 References

- 231 1. Alcon-LePoder S, Sivard P, Drouet MT, Talarmin A, Rice C, Flamand M (2006)
- 232 Secretion of flaviviral non-structural protein NS1: from diagnosis to
- 233 pathogenesis. *Novartis Found Symp* 277:233-247; discussion 247-253
- 234 2. Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DI, Nogueira RM,
- 235 Kubelka CF (2006) NK cells, displaying early activation, cytotoxicity and
- 236 adhesion molecules, are associated with mild dengue disease. *Clin Exp Immunol*
- 237 143:345-356
- 238 3. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA,
- 239 Bjorklund AT, Flodstrom-Tullberg M, Michaelsson J, Rottenberg ME, Guzman
- 240 CA, Ljunggren HG, Malmberg KJ (2010) Expression patterns of NKG2A, KIR,
- 241 and CD57 define a process of CD56dim NK-cell differentiation uncoupled from
- 242 NK-cell education. *Blood* 116:3853-3864
- 243 4. Caligiuri MA (2008) Human natural killer cells. *Blood* 112:461-469
- 244 5. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson
- 245 WE, Caligiuri MA (2001) Human natural killer cells: a unique innate
- 246 immunoregulatory role for the CD56(bright) subset. *Blood* 97:3146-3151
- 247 6. Farag SS, Caligiuri MA (2006) Human natural killer cell development and
- 248 biology. *Blood Rev* 20:123-137
- 249 7. Fleit HB, Wright SD, Unkeless JC (1982) Human neutrophil Fc gamma receptor
- 250 distribution and structure. *Proc Natl Acad Sci U S A* 79:3275-3279
- 251 8. Gayoso I, Sanchez-Correa B, Campos C, Alonso C, Pera A, Casado JG,
- 252 Morgado S, Tarazona R, Solana R (2011) Immunosenescence of human natural
- 253 killer cells. *J Innate Immun* 3:337-343
- 254 9. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak
- 255 A, Kurane I, Rothman AL, Ennis FA (1999) Early CD69 expression on
- 256 peripheral blood lymphocytes from children with dengue hemorrhagic fever. *J*
- 257 *Infect Dis* 180:1429-1435
- 258 10. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazques S, Delgado I,
- 259 Halstead SB (2000) Epidemiologic studies on Dengue in Santiago de Cuba,
- 260 1997. *Am J Epidemiol* 152:793-799; discussion 804
- 261 11. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S,
- 262 Nimmannitya S, Soegijanto S, Vaughn DW, Endy TP (2002) Dengue
- 263 hemorrhagic fever in infants: research opportunities ignored. *Emerg Infect Dis*
- 264 8:1474-1479

- 265 12. Halstead SB (2007) Dengue. *Lancet* 370:1644-1652
- 266 13. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S,  
267 Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell  
268 KS, Rager-Zisman B, Despres P, Porgador A (2009) NKp44 receptor mediates  
269 interaction of the envelope glycoproteins from the West Nile and dengue viruses  
270 with NK cells. *J Immunol* 183:2610-2621
- 271 14. Kurane I, Hebblewaite D, Ennis FA (1986) Characterization with monoclonal  
272 antibodies of human lymphocytes active in natural killing and  
273 antibody-dependent cell-mediated cytotoxicity of dengue virus-infected cells.  
274 *Immunology* 58:429-436
- 275 15. Lee SH, Miyagi T, Biron CA (2007) Keeping NK cells in highly regulated  
276 antiviral warfare. *Trends Immunol* 28:252-259
- 277 16. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S,  
278 Vaughn DW, Nisalak A, Ennis FA, Rothman AL (2002) High circulating levels  
279 of the dengue virus nonstructural protein NS1 early in dengue illness correlate  
280 with the development of dengue hemorrhagic fever. *J Infect Dis* 186:1165-1168
- 281 17. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA,  
282 Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ (2009) A  
283 prospective nested case-control study of Dengue in infants: rethinking and  
284 refining the antibody-dependent enhancement dengue hemorrhagic fever model.  
285 *PLoS Med* 6:e1000171
- 286 18. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H,  
287 Norris PJ, Nixon DF, Lanier LL (2010) CD57 defines a functionally distinct  
288 population of mature NK cells in the human CD56dimCD16+ NK-cell subset.  
289 *Blood* 116:3865-3874
- 290 19. Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB,  
291 Kalinski P (2005) IL-18-induced CD83+CCR7+ NK helper cells. *J Exp Med*  
292 202:941-953
- 293 20. Mathew A, Rothman AL (2008) Understanding the contribution of cellular  
294 immunity to dengue disease pathogenesis. *Immunol Rev* 225:300-313
- 295 21. Navarro-Sanchez E, Despres P, Cedillo-Barron L (2005) Innate immune  
296 responses to dengue virus. *Arch Med Res* 36:425-435
- 297 22. Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M,  
298 Yoshida T, Saito A, Katakai Y, Akari H, Kurane I (2011) Common marmoset  
299 (*Callithrix jacchus*) as a primate model of dengue virus infection: development


- 300 of high levels of viremia and demonstration of protective immunity. *J Gen Virol*  
301 doi:10.1099/vir.0.031229-0
- 302 23. Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA (2007)  
303 The interplay between host and viral factors in shaping the outcome of  
304 cytomegalovirus infection. *Immunol Cell Biol* 85:46-54
- 305 24. Shresta S, Kyle JL, Robert Beatty P, Harris E (2004) Early activation of natural  
306 killer and B cells in response to primary dengue virus infection in A/J mice.  
307 *Virology* 319:262-273
- 308 25. Suwannasaen D, Romphruk A, Leelayuwat C, Lertmemongkolchai G (2010)  
309 Bystander T cells in human immune responses to dengue antigens. *BMC*  
310 *Immunol* 11:47
- 311 26. Vaughn DW, Green S, Kalayanaroj S, Innis BL, Nimmannitya S, Suntayakorn  
312 S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A (2000)  
313 Dengue viremia titer, antibody response pattern, and virus serotype correlate  
314 with disease severity. *J Infect Dis* 181:2-9
- 315 27. Wahid SF, Sanusi S, Zawawi MM, Ali RA (2000) A comparison of the pattern  
316 of liver involvement in dengue hemorrhagic fever with classic dengue fever.  
317 *Southeast Asian J Trop Med Public Health* 31:259-263
- 318 28. Woollard DJ, Haqshenas G, Dong X, Pratt BF, Kent SJ, Gowans EJ (2008)  
319 Virus-specific T-cell immunity correlates with control of GB virus B infection  
320 in marmosets. *J Virol* 82:3054-3060
- 321 29. Yoshida T, Saito A, Iwasaki Y, Iijima S, Kurosawa T, Katakai Y, Yasutomi Y,  
322 Reimann KA, Hayakawa T, Akari H (2010) Characterization of natural Killer  
323 cells in tamarins: a technical basis for studies of innate immunity. *Front*  
324 *Microbiol* doi: 10.3389/fmicb.2010.00128
- 325
- 326

326    **Conflict of Interest Statement:**

327    The authors declare that the research was conducted in the absence of any commercial  
328    or financial relationships that could be construed as a potential conflict of interest.


329

**Fig. 1**






**Fig. 2**



**Fig. 3**



## Supplementary Legends

### **Supplementary Figure 1. Ratios of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD20<sup>+</sup> B cells after administration of CD16 (3G8) antibody *in vivo* in tamarin.**

(A-C) Tamarin was administered with 50 mg/kg of 3G8 mAb. CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD20<sup>+</sup> B cells were determined in whole blood specimens. Tamarin: Tm 03-008.

**Supplementary Figure 2. Control antibody (MOPC-21) did not deplete CD16<sup>+</sup> cells *in vivo* in tamarins.** (A, B) Tamarins were administered with 50 mg/kg of the control antibody (MOPC-21). CD16<sup>+</sup> NK cell numbers were determined in whole blood specimens. Tamarins: Tm 03-012, Tm 06-013.

## Supplementary materials and methods

### **Animals**

All animal studies were conducted in accordance with the protocols of experimental procedures that were approved by the Animal Welfare and Animal Care Committee of the National Institute of Infectious Diseases, Japan, and the National Institute of Biomedical Innovation, Japan. One tamarin was used. Tamarins were caged singly at 27±2 °C in 50±10% humidity with a 12h light-dark cycle (lighting from 7:00 to 19:00) at Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba, Japan. Animal was fed twice a day with a standard tamarin diet supplemented with fruit, eggs and milk. Water was given *ad libitum*. All animals were in a healthy condition and confirmed to be negative for anti-dengue virus antibodies before inoculation with dengue virus [3].

## Cells

Cell culture was performed as previously described [3]. Vero cells were cultured in Minimum Essential Medium (MEM, Sigma) with 10% heat-inactivated fetal bovine serum (FBS, GIBCO) and 1% non-essential amino acid (NEAA, Sigma) at 37 °C in 5 % CO<sub>2</sub>. C6/36 cells were cultured in MEM with 10% FBS and 1% NEAA at 28 °C in 5 % CO<sub>2</sub>.

## Virus

DENV strain was reported as previously described [3]. DENV type 2 (DENV-2), DHF0663 strain (Accession no. AB189122) strain was used for inoculation studies. The DENV-2, DHF0663 strain was isolated from a DHF case in Indonesia. The DENV-2 isolated clinical samples were propagated with C6/36 cells and were used within 4 passages on C6/36 cells. Culture supernatant from infected C6/36 cells was centrifuged at 3,000 rpm for 5 min to remove cell debris, and then stored at -80 °C until use.

## *In vivo* depletion of CD16 positive cells

Mouse anti-human CD16 (3G8) mAb [2] and a mouse immunoglobulin G (IgG1κ) isotype-matched irrelevant control antibody (MOPC-21) were produced in serum-free medium and purified using protein A affinity chromatography [1]. Endotoxin levels were lower than 1EU/mg. Administration of CD16 antibody (3G8) or control antibody (MOPC-21) was performed as previously described [4]. The each antibody was administered to tamarin (Tm 03-008, Tm 03-012, Tm 06-013) intravenously at 50 mg/kg at a rate of 18 ml/min using a syringe pump. Lymphocyte subsets were monitored for 2~3 weeks after the administration.

## Infection of marmosets with DENV

In the challenge study, profiling of the key adaptive and innate immune cells in marmosets after serotype 2 of DENV (DENV-2) was examined. Marmosets were inoculated subcutaneously in the back with  $1.8 \times 10^4$  or  $1.8 \times 10^5$  PFU of the DENV-2 DHF0663 strain [3]. Blood samples were collected on day 0, 1, 3, 7, 14, and 21 after inoculation. Blood samples were used for FACS analysis. Inoculation with DENV and blood drawing were performed under anesthesia with 5 mg/kg of ketamine hydrochloride. Day 0 was defined as the day of virus inoculation.

## Flow cytometry

Flow cytometry was performed as previously described [4]. Fifty microliters of whole blood from tamarins was stained with combinations of fluorescence-conjugated monoclonal antibodies (mAb): anti-CD3 (SP34-2; Becton Dickinson), anti-CD4 (L200; BD Pharmingen), anti-CD8 (CLB-T8/4H8; Sanquin), anti-CD16 (3G8; BD Pharmingen) and anti-CD20 (H299; BECKMAN COULTER). Then, erythrocytes were lysed with FACS lysing solution (Becton Dickinson). After having been washed with sample buffer containing phosphate-buffered saline (PBS), 1% fetal calf serum (FCS), and 1% formaldehyde, the labeled cells were resuspended in the sample buffer. The expression of the immunolabeled molecules on the lymphocytes was analyzed with a FACSCanto II flow cytometer (Becton Dickinson).


## References

1. Choi EI, Reimann KA, Letvin NL (2008) In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. J

Viol 82:6758-6761

2. Fleit HB, Wright SD, Unkeless JC (1982) Human neutrophil Fc gamma receptor distribution and structure. *Proc Natl Acad Sci U S A* 79:3275-3279
3. Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M, Yoshida T, Saito A, Katakai Y, Akari H, Kurane I (2011) Common marmoset (*Callithrix jacchus*) as a primate model of dengue virus infection: development of high levels of viremia and demonstration of protective immunity. *J Gen Virol* doi:10.1099/vir.0.031229-0
4. Yoshida T, Saito A, Iwasaki Y, Iijima S, Kurosawa T, Katakai Y, Yasutomi Y, Reimann KA, Hayakawa T, Akari H (2010) Characterization of natural Killer cells in tamarins: a technical basis for studies of innate immunity. *Front Microbiol* doi: 10.3389/fmicb.2010.00128

## Supplementary Fig. 1



## Supplementary Fig. 2

